BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31505083)

  • 1. Data linkage to monitor hepatitis C-associated end-stage liver disease and hepatocellular carcinoma inpatient stays in England.
    Ireland G; Simmons R; Hickman M; Harris R; Ramsay M; Sabin C; Mandal S
    J Viral Hepat; 2020 Jan; 27(1):20-27. PubMed ID: 31505083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infection With Hepatitis C Virus Genotype 3 Is an Independent Risk Factor for End-Stage Liver Disease, Hepatocellular Carcinoma, and Liver-Related Death.
    McMahon BJ; Bruden D; Townshend-Bulson L; Simons B; Spradling P; Livingston S; Gove J; Hewitt A; Plotnik J; Homan C; Espera H; Negus S; Snowball M; Barbour Y; Bruce M; Gounder P
    Clin Gastroenterol Hepatol; 2017 Mar; 15(3):431-437.e2. PubMed ID: 27765729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of end-stage liver disease, hepatocellular carcinoma, and liver-related death by fibrosis stage in the hepatitis C Alaska Cohort.
    Bruden DJT; McMahon BJ; Townshend-Bulson L; Gounder P; Gove J; Plotnik J; Homan C; Hewitt A; Barbour Y; Spradling PR; Simons BC; McArdle S; Bruce M
    Hepatology; 2017 Jul; 66(1):37-45. PubMed ID: 28195349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias?
    Goodgame B; Shaheen NJ; Galanko J; El-Serag HB
    Am J Gastroenterol; 2003 Nov; 98(11):2535-42. PubMed ID: 14638360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons.
    Ryom L; Lundgren JD; De Wit S; Kovari H; Reiss P; Law M; El-Sadr W; Monforte AD; Mocroft A; Smith C; Fontas E; Dabis F; Phillips A; Sabin C;
    AIDS; 2016 Jul; 30(11):1731-43. PubMed ID: 26752282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ambulatory end-stage liver disease in Ghana; patient profile and utility of alpha fetoprotein and aspartate aminotransferase: platelet ratio index.
    Nartey YA; Awuku YA; Agyei-Nkansah A; Duah A; Bampoh SA; Ayawin J; Asibey SO; Björkström NK; Ye W; Afihene MY; Roberts LR; Plymoth A
    BMC Gastroenterol; 2020 Dec; 20(1):428. PubMed ID: 33357229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus: Impact of Hepatitis C Virus Treatment.
    Mocroft A; Lundgren J; Gerstoft J; Rasmussen LD; Bhagani S; Aho I; Pradier C; Bogner JR; Mussini C; Uberti Foppa C; Maltez F; Laguno M; Wandeler G; Falconer K; Trofimova T; Borodulina E; Jevtovic D; Bakowska E; Kase K; Kyselyova G; Haubrich R; Rockstroh JK; Peters L;
    Clin Infect Dis; 2020 May; 70(10):2131-2140. PubMed ID: 31504296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders.
    Fransen van de Putte DE; Makris M; Fischer K; Yee TT; Kirk L; van Erpecum KJ; Patch D; Posthouwer D; Mauser-Bunschoten EP
    J Hepatol; 2014 Jan; 60(1):39-45. PubMed ID: 23978717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The burden of hepatitis C in England.
    Sweeting MJ; De Angelis D; Brant LJ; Harris HE; Mann AG; Ramsay ME
    J Viral Hepat; 2007 Aug; 14(8):570-6. PubMed ID: 17650291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus genotype 3 was associated with the development of hepatocellular carcinoma in Korea.
    Lee SS; Kim CY; Kim BR; Cha RR; Kim WS; Kim JJ; Lee JM; Kim HJ; Ha CY; Kim HJ; Kim TH; Jung WT; Lee OJ
    J Viral Hepat; 2019 Apr; 26(4):459-465. PubMed ID: 30516858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005-2014.
    Kim D; Cholankeril G; Li AA; Kim W; Tighe SP; Hameed B; Kwo PY; Harrison SA; Younossi ZM; Ahmed A
    Liver Int; 2019 Sep; 39(9):1661-1671. PubMed ID: 31081997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma.
    Lee MH; Yang HI; Lu SN; Jen CL; You SL; Wang LY; L'Italien G; Chen CJ; Yuan Y;
    Int J Cancer; 2014 Sep; 135(5):1119-26. PubMed ID: 24482200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of hepatocellular carcinoma in patients with chronic liver disease due to hepatitis B or C and coinfected with the human immunodeficiency virus: A retrospective cohort study.
    Marcon PDS; Tovo CV; Kliemann DA; Fisch P; de Mattos AA
    World J Gastroenterol; 2018 Feb; 24(5):613-622. PubMed ID: 29434450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver-related mortality among people with hepatitis B and C: Evaluation of definitions based on linked healthcare administrative datasets.
    Shah SHBU; Alavi M; Hajarizadeh B; Matthews G; Valerio H; Dore GJ
    J Viral Hepat; 2023 Jun; 30(6):520-529. PubMed ID: 36843500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse outcomes in Alaska natives who recovered from or have chronic hepatitis C infection.
    McMahon BJ; Bruden D; Bruce MG; Livingston S; Christensen C; Homan C; Hennessy TW; Williams J; Sullivan D; Rosen HR; Gretch D
    Gastroenterology; 2010 Mar; 138(3):922-31.e1. PubMed ID: 19909749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003.
    Tanaka H; Imai Y; Hiramatsu N; Ito Y; Imanaka K; Oshita M; Hijioka T; Katayama K; Yabuuchi I; Yoshihara H; Inoue A; Kato M; Takehara T; Tamura S; Kasahara A; Hayashi N; Tsukuma H
    Ann Intern Med; 2008 Jun; 148(11):820-6. PubMed ID: 18519928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
    Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H
    Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetes and Cirrhosis Are Risk Factors for Hepatocellular Carcinoma After Successful Treatment of Chronic Hepatitis C.
    Hedenstierna M; Nangarhari A; Weiland O; Aleman S
    Clin Infect Dis; 2016 Sep; 63(6):723-9. PubMed ID: 27282709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan.
    Chen CL; Yang HI; Yang WS; Liu CJ; Chen PJ; You SL; Wang LY; Sun CA; Lu SN; Chen DS; Chen CJ
    Gastroenterology; 2008 Jul; 135(1):111-21. PubMed ID: 18505690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.